StockData
Neurogene Inc. logo

Neurogene Inc. (NGNE) stock

NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$23.10−0.20 (-0.86%)

Close on Nov 17, 2026Market cap $462.26MP/E –Yield –

Neurogene total assets

Total assets on the balance sheet at the end of each period.

Neurogene's total assets was $244.36M at Jun 30, 2026. For fiscal 2025 it was $288.60M, down 14.0% from the year before. Over ten years it grew 9.8% a year on average. The highest annual figure on record is $335.73M in fiscal 2024.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$288.60M-14.0%
FY2024Dec 31, 2024$335.73M+50.8%
FY2023Dec 31, 2023$222.57M+103.7%
FY2022Dec 31, 2022$109.27M-33.1%
FY2021Dec 31, 2021$163.26M-22.4%
FY2020Dec 31, 2020$210.52M+43.2%
FY2019Dec 31, 2019$147.02M+89.4%
FY2018Dec 31, 2018$77.62M-29.6%
FY2017Dec 31, 2017$110.33M-28.5%
FY2016Dec 31, 2016$154.38M+36.2%
FY2015Dec 31, 2015$113.34M+173.6%
FY2014Dec 31, 2014$41.42M+164.7%
FY2013Dec 31, 2013$15.65M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$244.36M-17.8%
Q1 FY2026Mar 31, 2026$263.14M-16.5%
Q4 FY2025Dec 31, 2025$288.60M-14.0%
Q3 FY2025Sep 30, 2025$287.83M+75.4%
Q2 FY2025Jun 30, 2025$297.32M+65.3%
Q1 FY2025Mar 31, 2025$315.30M+61.4%
Q4 FY2024Dec 31, 2024$335.73M+50.8%
Q3 FY2024Sep 30, 2024$164.12M+83.2%
Q2 FY2024Jun 30, 2024$179.82M+91.3%
Q1 FY2024Mar 31, 2024$195.35M+98.4%
Q4 FY2023Dec 31, 2023$222.57M+103.7%
Q3 FY2023Sep 30, 2023$89.59M-29.2%
Q2 FY2023Jun 30, 2023$94.01M-31.4%
Q1 FY2023Mar 31, 2023$98.46M-34.0%
Q4 FY2022Dec 31, 2022$109.27M-33.1%
Q3 FY2022Sep 30, 2022$126.58M-28.1%
Q2 FY2022Jun 30, 2022$137.02M-26.7%
Q1 FY2022Mar 31, 2022$149.13M-25.5%
Q4 FY2021Dec 31, 2021$163.26M-22.4%
Q3 FY2021Sep 30, 2021$175.93M-20.6%
Q2 FY2021Jun 30, 2021$187.02M+28.7%
Q1 FY2021Mar 31, 2021$200.10M+30.7%
Q4 FY2020Dec 31, 2020$210.52M+43.2%
Q3 FY2020Sep 30, 2020$221.69M+217.6%
Q2 FY2020Jun 30, 2020$145.32M+97.1%
Q1 FY2020Mar 31, 2020$153.05M+102.9%
Q4 FY2019Dec 31, 2019$147.02M+89.4%
Q3 FY2019Sep 30, 2019$69.79M-20.5%
Q2 FY2019Jun 30, 2019$73.74M-29.4%
Q1 FY2019Mar 31, 2019$75.43M-21.1%
Q4 FY2018Dec 31, 2018$77.62M-29.6%
Q3 FY2018Sep 30, 2018$87.81M-27.8%
Q2 FY2018Jun 30, 2018$104.43M-21.7%
Q1 FY2018Mar 31, 2018$95.62M-33.3%
Q4 FY2017Dec 31, 2017$110.33M-28.5%
Q3 FY2017Sep 30, 2017$121.60M-25.9%
Q2 FY2017Jun 30, 2017$133.28M–
Q1 FY2017Mar 31, 2017$143.33M–
Q4 FY2016Dec 31, 2016$154.38M–
Q3 FY2016Sep 30, 2016$164.07M–

More Neurogene figures

See a number that looks wrong?